SCHEMBL5040838

SCHEMBL5040838

COC(=O)Nc1nc2c(OC)cccc2o1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
TP53 P04637 1/20 0.44
DYRK1A Q13627 1/20 0.43
AGPAT2 O15120 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
HCRTR1 O43613 3/20 0.41
HCRTR2 O43614 2/20 0.41
ABL1 P00519 1/20 0.41
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
EDNRA P25101 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11195754 0.76 NPC1 (0.70) NPC1RAB9ASMN1; SMN2TP53AGPAT2
SCHEMBL31213015 0.75 ALDH1A1 (0.54) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL5037842 0.75 AGPAT2 (0.39) NPC1RAB9ASMN1; SMN2TP53DYRK1A
SCHEMBL5033935 0.75 ALDH1A1 (0.38) NPC1RAB9ASMN1; SMN2DYRK1AAGPAT2
SCHEMBL6958263 0.75 LMNA (0.47) NPC1RAB9ASMN1; SMN2DYRK1AKDM4E
SCHEMBL5036203 0.72 ALDH1A1 (0.41) NPC1RAB9ATP53ABL1KDM4E
SCHEMBL5036747 0.72 KMT2A (0.39) NPC1RAB9ASMN1; SMN2TP53L3MBTL1
SCHEMBL20931281 0.72 ELANE (0.49) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL9768577 0.72 NQO2 (0.46) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL20818979 0.71 EDNRA (0.43) NPC1RAB9ASMN1; SMN2TP53DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1587799-B1 BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS HOFFMANN LA ROCHE (CH) 2008-03-12 EP disclosed
EP-1587799-B1 BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS HOFFMANN LA ROCHE (CH) 2008-03-12 EP disclosed
US-6992083-B2 deiodination/arylation, acylation or hydrogenation of a substituted 4-methoxy-bezoxazole derivative; adenosine receptor ligands; Parkinson's and Alzheimer's Diseases; 2-Chloromethyl-N-[7-(4-fluoro-phenyl)-4-methoxy-benzooxazol-2-yl]-isonicotinamide HOFFMAN-LA ROCHE INC. (US) 2006-01-31 US disclosed
EP-1587799-A1 BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-26 EP disclosed
US-20040152702-A1 Benzoxazol derivatives F. HOFFMANN-LA ROCHE AG (CH) 2004-08-05 US disclosed
WO-2004063177-A1 BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-29 WO disclosed
WO-2004063177-A1 BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152702-A1 Benzoxazol derivatives P2RX3, P2RX2, P2RX1 NPC1 613/4885RAB9A 2421/4885SMN1; SMN2 2388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.